Develops small-molecule medicines designed to target mutations driving cancers and vascular malformations, for patients with those diseases.
10-K for FY2025, filed Mar 12, 2026OnKure Therapeutics, Inc. (“OnKure”, “we”, “us” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery…View ↗
Our lead product candidate, OKI-219, is a highly selective inhibitor of PI3Kα harboring the H1047R mutation (“PI3KαH1047R”) that has a much…View ↗
Expand the development of PI3Ka inhibitors beyond breast cancer by harnessing the knowledge gained by our discovery team from understanding…View ↗
$3.4M
10-K for FY2025, filed Mar 12, 2026
$3.4M ↗No. It lost $59.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$17.8MView ↗
From mitochondrial disease to targeted drugs
The older report centered on mavodelpar for rare genetic mitochondrial diseases; the latest centers on mutation-targeted drugs for breast cancer and includes a vascular-malformations program.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 12, 2026Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare…View ↗
Competes with Novartis, Astra Zeneca, Celcuity, Menarini, Totus Medicines, Relay Therapeutics, Scorpion Therapeutics, and Synnovation Therapeutics
10-K for FY2025, filed Mar 12, 2026There are multiple PI3Kα-pathway targeted agents either approved or under clinical development that may compete with OKI-219 and our…View ↗
Loading...